Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 12/20 | 0.65 |
| ▸ | SRC | P12931 | 8/20 | 0.65 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | CLK1 | P49759 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928078 | 0.84 | FGFR1 (0.47) | FGFR1SRCKDRCLK1GAA | |
| SCHEMBL8134775 | 0.79 | FGFR1 (1.00) | FGFR1SRCKDREGFRFGFR2 | |
| SCHEMBL8807633 | 0.79 | FGFR1 (1.00) | FGFR1SRCKDREGFRFGFR2 | |
| SCHEMBL5042995 | 0.77 | DHFR (0.46) | FGFR1SRCCLK1EGFRLMNA | |
| SCHEMBL28156921 | 0.76 | FGFR1 (0.62) | FGFR1SRCKDRCLK1GAA | |
| SCHEMBL27639327 | 0.75 | WEE1 (0.39) | FGFR1SRCEGFRLMNA | |
| SCHEMBL10837807 | 0.75 | FGFR1 (0.49) | FGFR1SRCCLK1EGFRGAA | |
| SCHEMBL11108289 | 0.75 | FGFR1 (0.68) | FGFR1SRCKDREGFRFGFR2 | |
| SCHEMBL10838139 | 0.72 | MEN1 (0.46) | CLK1GAACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10838388 | 0.72 | NPC1 (0.68) | FGFR1SRCCLK1GAACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372648-B1 | TIE2 RECEPTOR KINASE INHIBITORS FOR TREATING ANGIOGENIC DISEASES | SMITHKLINE BEECHAM CORP (US) | 2006-03-15 | — | — | EP | disclosed |
| US-7005434-B2 | Compounds and uses thereof | SB CORPORATION (US) | 2006-02-28 | — | — | US | disclosed |
| EP-1372648-A4 | TIE2 RECEPTOR KINASE INHIBITORS FOR TREATING ANGIOGENIC DISEASES | SMITHKLINE BEECHAM CORP (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040048888-A1 | Novel compounds and uses thereof | SMITHKLINE BEECHAM CORPORATION | 2004-03-11 | — | — | US | disclosed |
| EP-1372648-A2 | TIE2 RECEPTOR KINASE INHIBITORS FOR TREATING ANGIOGENIC DISEASES | SmithKline Beecham Corporation (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002060382-A2 | NOVEL COMPOUNDS AND USES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048888-A1 | Novel compounds and uses thereof | TEK, TIE1, KDR | FGFR1 24/4885SRC 1144/4885KDR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.